Core Viewpoint - The C3.ai class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly in relation to the health of CEO Thomas M. Siebel, leading to significant stock price declines following disappointing financial results [1][4][5]. Group 1: Lawsuit Details - The lawsuit, titled Liggett v. C3.ai, Inc., seeks to represent purchasers of C3.ai securities and claims violations of the Securities Exchange Act of 1934 [1][3]. - The lawsuit alleges that C3.ai's optimistic growth reports were misleading and overly reliant on the CEO's health, which was not disclosed adequately to investors [4][5]. - Following the announcement of disappointing preliminary financial results for Q1 FY 2026 and a reduction in revenue guidance, C3.ai's stock price fell by more than 25% [5]. Group 2: Legal Process - Investors who suffered losses can apply to be the lead plaintiff in the class action lawsuit, with the deadline for motions set for October 21, 2025 [2][6]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [6]. Group 3: Company Background - C3.ai operates as an enterprise artificial intelligence application software company [3].

Core Viewpoint - A securities class action lawsuit has been filed against C3.ai, Inc. for allegedly misleading investors by making overly positive statements while concealing material adverse facts [2][6]. Allegations - The lawsuit claims that C3.ai and its executives misled investors regarding the company's performance and potential [2]. - The CEO's health issues significantly hindered the company's ability to close deals, and management failed to minimize the impact of these health issues on operations [6]. Triggering Event - On August 8, 2025, C3.ai announced disappointing preliminary Q1 FY2026 results and cut full-year revenue guidance, attributing weak sales to "reorganization with new leadership" and the CEO's health problems [6]. Stock Impact - Following the announcement on August 8, 2025, C3.ai's stock closed at $22.13 per share and fell to $16.47 per share by August 11, 2025, representing a drop of approximately 25.6% in a single trading day [6]. Next Steps for Investors - Investors who suffered losses can seek appointment as lead plaintiff prior to October 21, 2025, by contacting Wolf Haldenstein [2][6].

Core Viewpoint - A class action securities lawsuit has been filed against C3.ai, Inc. due to alleged securities fraud that negatively impacted investors between February 26, 2025, and August 8, 2025 [1][2] Company Performance - The lawsuit claims that C3.ai's management provided overly positive statements while concealing significant adverse facts about the company's growth, particularly the health issues of its CEO, which affected deal closures [2] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health problems [2] - Following the announcement, C3.ai's stock price plummeted from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of approximately 25.58% in just one day [2] Legal Proceedings - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request to be appointed as lead plaintiff in the lawsuit [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. for allegedly misleading investors about the impact of its CEO's health on the company's business prospects [1][2]. Group 1: Allegations and Impact - The lawsuit claims that C3.ai failed to disclose how the CEO's health affected the company's ability to close deals and that management was ineffective in mitigating this impact [2]. - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing the poor performance to "the reorganization with new leadership" and the CEO's health issues [3]. - Following this announcement, C3.ai's stock price dropped from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of over 25% [3]. Group 2: Legal Proceedings - Shareholders interested in serving as lead plaintiffs in the class action must submit their papers to the court by October 21, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Company Background - Robbins LLP, the firm handling the case, has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. by Berger Montague on behalf of investors who acquired shares during the specified class period, alleging misleading statements regarding the company's growth and CEO's health [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased C3.ai shares from February 26, 2025, to August 8, 2025 [1][2]. - Investors have until October 21, 2025, to seek appointment as lead plaintiff [2]. Group 2: Allegations Against C3.ai - The complaint claims that C3.ai and its executives made materially false statements and failed to disclose adverse information about the company's growth prospects and the CEO's health [3]. - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its full-year revenue guidance, attributing this to leadership reorganization and the CEO's health [3]. Group 3: Stock Price Impact - Following the announcement on August 8, 2025, C3.ai's stock price fell from $22.13 per share to $16.47 per share by August 11, representing a decline of over 25% [3].

Core Viewpoint - A securities class action lawsuit has been filed against C3.ai, Inc. for allegedly misleading investors regarding its revenue outlook and the impact of CEO Thomas M. Siebel's health on the company's profitability [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of individuals or entities that acquired C3.ai shares between February 26, 2025, and August 8, 2025 [1]. - The Complaint claims that the defendants created a false impression of C3.ai's financial health and growth potential while downplaying risks associated with the CEO's health [2]. Group 2: Investor Information - Investors who purchased C3.ai shares are encouraged to contact the law firm before the lead plaintiff motion deadline on October 21, 2025 [3]. - The lead plaintiff will represent the interests of other class members in the litigation process [3].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against C3.ai, Inc. for alleged misrepresentations regarding the company's business and the impact of the CEO's health on its operations [1][2]. Group 1: Lawsuit Details - The lawsuit claims that C3.ai's management failed to address the significant impact of the CEO's health on the company's ability to close deals and execute its profit and growth potential [2]. - Investors who purchased C3.ai securities between February 26, 2025, and August 8, 2025, are included in the class [1]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file papers by October 21, 2025, and representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [4].

Group 1 - The investor has a contrarian investment style, focusing on high-risk, illiquid options and shares, with a portfolio split of approximately 50%-50% [1] - The investment strategy involves buying stocks that have recently experienced sell-offs due to non-recurrent events, especially when insiders are purchasing shares at lower prices [1] - Fundamental analysis is employed to assess the health of companies, their leverage, and to compare financial ratios with sector and industry averages [1] Group 2 - Technical analysis is utilized to optimize entry and exit points, primarily using multicolor lines for support and resistance levels on weekly charts [1] - The investor conducts professional background checks on insiders who purchase shares after sell-offs to ensure credibility [1] - The investment timeframe typically ranges from 3 to 24 months, indicating a medium-term investment horizon [1]

ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against C3.ai, Inc. (“C3” or the “Company”) (NYSE: AI). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding the true state of C3’s growth; specifically, that its CEO’s health was having a significant impact on C3’s ability to close deals. If you purchased shares of C3 between February 26, 2025 and August 8, 2025, and ...

Core Viewpoint - The C3.ai class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly in relation to CEO Thomas M. Siebel's health concerns, leading to significant stock price declines following disappointing financial results [3][4]. Group 1: Lawsuit Details - The lawsuit, titled Liggett v. C3.ai, Inc., seeks to represent purchasers of C3.ai securities and claims violations of the Securities Exchange Act of 1934 [1][2]. - Allegations include creating a false impression of reliable revenue projections and minimizing risks associated with the CEO's health, which ultimately did not align with the company's actual performance [3]. Group 2: Financial Impact - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal year 2026 and reduced its revenue guidance for the full fiscal year, attributing these issues to leadership reorganization and the CEO's health [4]. - Following this announcement, C3.ai's stock price fell by more than 25% [4]. Group 3: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased C3.ai securities during the class period to seek appointment as lead plaintiff, representing the interests of the class [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been recognized for its significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [6].